At Kedrion Biopharma, our mission is to enhance lives through our work in the field of rare and ultra-rare diseases.

With a global community of 5,200 people, we are committed to collecting plasma and producing plasma-derived therapies that treat and prevent rare and debilitating conditions such as Coagulation and Neurological Disorders, Immunodeficiencies, and Rh sensitization.

Our extensive network includes 68 plasma collection centers operated by KEDPLASMA in the United States, 8 centers managed by UNICAplasma in the Czech Republic, and 7 production facilities across 5 countries. This infrastructure enables us to distribute 38 life-enhancing and life-saving products in over 100 countries, positioning us as the fifth largest player in the plasma-derived sector worldwide.

With our dedication to developing solutions that address unmet medical needs in rare and ultra-rare diseases, we envision a world where the union of science and care knows no bounds.

In partnership with the medical and scientific community, institutions, patient advocacy groups, and research organizations, we drive sustainable innovation and improve patient care.

What sets us apart from other biopharma companies is our commitment to every detail, every person, every interaction. Whether engaging with donors, supporting patients, empowering our employees, every connection we make impacts someone, somewhere. We call these “rare connections”.